ReviewCurrent heart failure reports2018
Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure.
Review in Current heart failure reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Clinical Utility of the TRENDS Remote Monitoring Function Integrated into a Wearable Cardioverter-Defibrillator.Sensors (Basel, Switzerland) · 2026Article
- Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study.European heart journal · 2025Observational
- A review on wearable cardioverter-defibrillators in clinical practice for sudden cardiac death prevention and heart failure management.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Review
- Usage of the wearable cardioverter-defibrillator during pregnancy.International journal of cardiology. Heart & vasculature · 2022Article
- Wearable Devices for Physical Monitoring of Heart: A Review.Biosensors · 2022Review
- Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology-A PROLONG-II Substudy.Sensors (Basel, Switzerland) · 2022Article
- Experience with a Wearable Cardioverter-defibrillator in 436 Patients.The Journal of innovations in cardiac rhythm management · 2022Article
- Extended follow-up after wearable cardioverter-defibrillator period: the PROLONG-II study.ESC heart failure · 2021Article
- Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverter-Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction.Sensors (Basel, Switzerland) · 2021Article
- Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.Journal of medical case reports · 2021Article
- Smart Wearables for Cardiac Monitoring-Real-World Use beyond Atrial Fibrillation.Sensors (Basel, Switzerland) · 2021Review
- Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Observational
- The Treatment of Heart Failure with Reduced Ejection Fraction.Deutsches Arzteblatt international · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe wearable defibrillator (WCD) was shown to be safe and effective in detecting and terminating ventricular tachyarrhythmias and therefore allows temporary protection from sudden cardiac death. This review gives an overview of the current data on WCD in newly diagnosed cardiomyopathy. RECENT
findingsPatients with newly diagnosed heart failure and reduced LVEF appear to have an increased risk of ventricular tachyarrhythmias, which may decrease over time when heart failure medication is optimized and left ventricular function improves. This was shown to apply for patients with ischemic and non-ischemic cardiomyopathy, including peripartum cardiomyopathy. Prolongation of the WCD period may support to further optimization of heart failure medication, by protecting the patient from sudden cardiac death during this time and to avoid untimely ICD implantation. The WCD should be considered in structured patient management for newly diagnosed heart failure during the early phase of the disease. Careful patient selection, structured patient management, and patient's compliance is crucial for a successful WCD strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.